• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Streamex Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Other Events, Financial Statements and Exhibits

    3/6/26 4:01:51 PM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $STEX alert in real time by email
    false 0001530766 0001530766 2026-03-03 2026-03-03 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    March 3, 2026

    Date of Report (Date of earliest event reported)

     

    STREAMEX CORP.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-38659   26-4333375
    (State   (Commission   (I.R.S. Employer
    of incorporation)   File Number)   Identification Number)

     

    2431 Aloma Avenue, Suite 243

    Winter Park, Florida 32792

    (Address of principal executive offices) (Zip code)

     

    (203) 409-5444

    (Registrant’s telephone number, including area code)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading symbol(s)   Name of each exchange on which registered
    Common Stock, par value $0.001 per share   STEX   The NASDAQ Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 1.01 Entry into a Material Definitive Agreement

     

    On March 3, 2026, Streamex Corp. (the “Company”) executed an offer letter with Shawn Matthews (such offer letter, the “Matthews Offer Letter”), in connection with Mr. Matthew’s appointment as a non-employee director of the board of directors (“Board”) of the Company. Mr. Matthews’ term of office will continue until the next annual meeting of the Company’s stockholders, or until his successor is duly elected and qualified, or his earlier death, resignation or removal. Pursuant to the Matthews Offer Letter, Mr. Matthews will serve as a non-employee director of the Board and receive compensation consistent with the Company’s non-employee director compensation policy, as in effect from time to time. Under the Company’s current policy, Mr. Matthews is entitled to an annual cash retainer of $40,000, as well as an additional annual retainer of $25,000 for each Board committee on which he serves. Mr. Matthews received a restricted stock award for 100,000 shares of the Company’s common stock, par value $0.001 (“Common Stock”), in connection with such appointment. Mr. Matthews is also eligible to receive additional annual equity compensation, the amount and form of which will be determined by the Company’s Compensation Committee (“Compensation Committee”) in accordance with the Company’s equity compensation policies. The Company will provide Mr. Matthews with the same indemnification rights afforded to its other directors under its governing documents and applicable law, including the advancement of expenses to the fullest extent permitted. Additionally, the Company will maintain directors and officers liability insurance covering Mr. Matthews in his capacity as a director, on terms no less favorable than those applicable to other members of the Board. Such coverage will remain in effect for the duration of Mr. Matthews’ duration of service and for any applicable tail period following his departure, as required by law or Company policy.

     

    The foregoing description of the Matthews Offer Letter does not purport to be complete and is qualified in its entirety by reference to the full text of the Matthews Offer Letter, a copy of which is filed with this Current Report on Form 8-K as Exhibit 10.1.

     

    Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     

    The disclosures in this Current Report on Form 8-K under Item 1.01 are incorporated herein by reference.

     

    On March 3, 2026, the Board appointed Mr. Shawn Matthews as an independent director of the Board and as a member of the Compensation Committee, such appointment effective upon his acceptance of the Matthews Offer Letter. Mr. Matthews’ term of office will continue until the next annual meeting of the Company’s stockholders, or until his successor is duly elected and qualified, or his earlier death, resignation or removal.

     

    Shawn Matthews is currently the Founder and Chief Investment Officer of Hondius Capital Management, a global alternative asset manager. In this role, he has oversight of and responsibility for all firm investments. Mr. Matthews has been actively investing in global markets for over 30 years, with the majority of his career focused on trading across asset classes. Prior to founding Hondius Capital Management, Mr. Matthews served as Chief Executive Officer of Cantor Fitzgerald & Co. (“Cantor Fitzgerald”) from 2009 through April 2018. Before becoming Chief Executive Officer at Cantor Fitzgerald, he held a number of senior investment leadership roles there, including Head of Capital Markets and Head of Mortgage Trading. Earlier in his career, Mr. Matthews worked as a fixed income derivatives trader, traded privatization certificates in Eastern Europe, and later founded both an equity-focused hedge fund, Alchemist Capital Management, and a fixed income broker-dealer, West Side Capital. Mr. Matthews holds a Bachelor of Science in Finance from Fairfield University and an MBA from Hofstra University.

     

    The terms of Mr. Matthews’ appointment as an independent director, including, amongst other things, compensation, are further set forth in the Matthews Offer Letter described in Item 1.01 of this Current Report on Form 8-K.

     

    Item 8.01 Other Events.

     

    On March 3, 2026, the Company issued a press release announcing the appointment of Shawn Matthews to its Board.

     

    A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits

     

    Exhibit Number   Description
    10.1   Offer Letter, dated March 3, 2026
    99.1   Press Release, dated March 3, 2026
    104   Cover Page Interactive Data File (formatted as Inline XBRL)

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: March 6, 2026 By: /s/ Karl Henry McPhie
      Name: Karl Henry McPhie
      Title: Chief Executive Officer

     

     

     

    Get the next $STEX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $STEX

    DatePrice TargetRatingAnalyst
    11/25/2025$12.00Buy
    Needham
    More analyst ratings

    $STEX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Interim Executive Chairman Lekstrom Morgan Lee bought $147,289 worth of shares (47,000 units at $3.13) (SEC Form 4)

    4/A - Streamex Corp. (0001530766) (Issuer)

    5/28/26 9:43:32 PM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Interim Executive Chairman Lekstrom Morgan Lee bought $49,980 worth of shares (34,000 units at $1.47) (SEC Form 4)

    4 - Streamex Corp. (0001530766) (Issuer)

    5/28/26 2:33:28 PM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Marciano Anthony Mark bought $20,052 worth of shares (17,745 units at $1.13), increasing direct ownership by 18% to 117,745 units (SEC Form 4)

    4 - Streamex Corp. (0001530766) (Issuer)

    5/22/26 4:05:25 PM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $STEX
    SEC Filings

    View All

    Streamex Corp. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Streamex Corp. (0001530766) (Filer)

    5/28/26 4:05:31 PM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Streamex Corp. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Streamex Corp. (0001530766) (Filer)

    5/27/26 6:05:10 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 10-Q filed by Streamex Corp.

    10-Q - Streamex Corp. (0001530766) (Filer)

    5/14/26 5:24:55 PM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $STEX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Streamex Corp. and Orca Announce Launch of 24/7 Decentralized Secondary Liquidity Infrastructure for Tokenized Securities; GLDY the Inaugural Asset

    WINTER PARK, Fla., May 27, 2026 (GLOBE NEWSWIRE) -- Streamex Corp. ("Streamex") (NASDAQ:STEX), a technology company building the tokenization ecosystem for all real-world assets beginning with commodities, today announced the launch of 24/7 secondary liquidity infrastructure for holders to trade tokenized securities, developed in partnership with Orca, a leading automated market maker (AMM) infrastructure provider on the Solana blockchain. Streamex's GLDY, a gold-backed, yield-bearing tokenized security, is the inaugural asset to trade on this infrastructure, in the "GLDY Pool on Orca." This marks a significant milestone for the broader tokenized real-world asset market as a vital piece of

    5/27/26 7:30:00 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Streamex Corp. Appoints Former Microsoft and PayPal Lead Product Designer Kori Handy as Vice President of Product and Design

    WINTER PARK, Fla., May 26, 2026 (GLOBE NEWSWIRE) -- Streamex Corp. ("Streamex" or the "Company") (NASDAQ:STEX), a technology company building the tokenization ecosystem for all real-world assets beginning with commodities, today announced the appointment of Kori Handy as Vice President of Product and Design. Kori brings 18 years of experience scaling fintech and SaaS platforms from zero to $2B+ in assets under management and more than 200 million users, and joins Streamex at a pivotal moment in the Company's growth trajectory. Highlights Kori brings nearly two decades of product, design, and startup leadership experience building fintech and SaaS platforms used by more than 200 million p

    5/26/26 7:30:00 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Streamex Corp. Provides Q1 2026 Earnings and Corporate Update Presentation Recap; Highlights New Partnerships & Key Updates

    WINTER PARK, Fla., May 21, 2026 (GLOBE NEWSWIRE) -- Streamex Corp. ("Streamex" or the "Company") (NASDAQ:STEX), a technology company focused on the tokenization of commodity real-world assets, yesterday hosted its Q1 2026 Earnings and Corporate Update Presentation, featuring remarks from Executive Chairman Morgan Lekstrom, Chief Executive Officer Henry McPhie, Chief Financial Officer Christine Plummer, and Chief Investment Officer Mitch Williams. The following is a summary of the key topics covered. Highlights Equity Trust - access to $72B+ and 359,000 U.S. tax-advantaged retirement accounts. An upcoming integration with Equity Trust Company opens GLDY to a distribution channel that prev

    5/21/26 7:30:00 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $STEX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Investment Officer Williams Mitchell Young sold $24,915 worth of shares (23,810 units at $1.05), decreasing direct ownership by 0.78% to 3,013,838 units (SEC Form 4) to satisfy withholding obligation

    4 - Streamex Corp. (0001530766) (Issuer)

    6/2/26 9:54:16 PM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form 4 filed by Interim Executive Chairman Lekstrom Morgan Lee

    4/A - Streamex Corp. (0001530766) (Issuer)

    5/28/26 9:44:06 PM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: Interim Executive Chairman Lekstrom Morgan Lee bought $147,289 worth of shares (47,000 units at $3.13) (SEC Form 4)

    4/A - Streamex Corp. (0001530766) (Issuer)

    5/28/26 9:43:32 PM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $STEX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Needham initiated coverage on Streamex Exchange Corporation with a new price target

    Needham initiated coverage of Streamex Exchange Corporation with a rating of Buy and set a new price target of $12.00

    11/25/25 7:59:34 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $STEX
    Leadership Updates

    Live Leadership Updates

    View All

    Streamex Corp. Appoints Former Microsoft and PayPal Lead Product Designer Kori Handy as Vice President of Product and Design

    WINTER PARK, Fla., May 26, 2026 (GLOBE NEWSWIRE) -- Streamex Corp. ("Streamex" or the "Company") (NASDAQ:STEX), a technology company building the tokenization ecosystem for all real-world assets beginning with commodities, today announced the appointment of Kori Handy as Vice President of Product and Design. Kori brings 18 years of experience scaling fintech and SaaS platforms from zero to $2B+ in assets under management and more than 200 million users, and joins Streamex at a pivotal moment in the Company's growth trajectory. Highlights Kori brings nearly two decades of product, design, and startup leadership experience building fintech and SaaS platforms used by more than 200 million p

    5/26/26 7:30:00 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Streamex Corp. Appoints Christine Plummer, Former Global Controller at Coinbase and Managing Director at Morgan Stanley, as Chief Financial Officer

    WINTER PARK, Fla., March 16, 2026 (GLOBE NEWSWIRE) -- Streamex Corp. ("Streamex" or the "Company") (NASDAQ:STEX), a technology and infrastructure company focused on the tokenization of commodity real-world assets, today announced the appointment of Christine Plummer, former Global Controller at Coinbase and Managing Director at Morgan Stanley, as Chief Financial Officer of Streamex. In this role, Ms. Plummer is expected to oversee the Company's global finance organization, including financial reporting, regulatory compliance, and financial operations as Streamex continues expanding its institutional platform and launching tokenized commodity products. Henry McPhie, Co-Founder & CEO of Str

    3/16/26 7:30:00 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Streamex Corp. Appoints Shawn Matthews, Former CEO of Cantor Fitzgerald & Co. & Founder and CIO of Hondius Capital Management, to Board of Directors

    WINTER PARK, Fla., March 03, 2026 (GLOBE NEWSWIRE) -- Streamex Corp. ("Streamex" or the "Company") (NASDAQ:STEX), a leader in institutional-grade tokenization and digital asset infrastructure, today is excited to announce the appointment of Shawn Matthews, Former CEO of Cantor Fitzgerald & Co. and Founder and Chief Investment Officer of Hondius Capital Management, to its Board of Directors. In this role, Mr. Matthews will bring decades of global investment, trading, and executive leadership experience to support Streamex's strategic growth, capital markets initiatives, and governance. He is joining as an independent director. Morgan Lekstrom, Co-Founder & Executive Chairman of Streamex sa

    3/3/26 7:30:00 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $STEX
    Financials

    Live finance-specific insights

    View All

    Streamex Corp. Provides Q1 2026 Earnings and Corporate Update Presentation Recap; Highlights New Partnerships & Key Updates

    WINTER PARK, Fla., May 21, 2026 (GLOBE NEWSWIRE) -- Streamex Corp. ("Streamex" or the "Company") (NASDAQ:STEX), a technology company focused on the tokenization of commodity real-world assets, yesterday hosted its Q1 2026 Earnings and Corporate Update Presentation, featuring remarks from Executive Chairman Morgan Lekstrom, Chief Executive Officer Henry McPhie, Chief Financial Officer Christine Plummer, and Chief Investment Officer Mitch Williams. The following is a summary of the key topics covered. Highlights Equity Trust - access to $72B+ and 359,000 U.S. tax-advantaged retirement accounts. An upcoming integration with Equity Trust Company opens GLDY to a distribution channel that prev

    5/21/26 7:30:00 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Streamex Corp. Announces April 2026 Yield Dividend Distribution for GLDY

    WINTER PARK, Fla., May 18, 2026 (GLOBE NEWSWIRE) -- Streamex Corp. ("Streamex" or the "Company") (NASDAQ:STEX), a technology company focused on the tokenization of commodity real-world assets, today announced the distribution of the second yield payment for GLDY, its gold-backed, yield-bearing tokenized security. The distribution covers the period from April 1st through April 30th, 2026. Yield Distribution Details GLDY's real-world yield is generated through Streamex's institutional gold leasing program, with proceeds from the program distributed to GLDY holders in the form of additional GLDY tokens monthly. Gold on lease is currently earning an annualized lease yield of 3.5%. For the mo

    5/18/26 7:30:00 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Streamex Corp. Reports Q1 2026 Financial Results and Announces Business & Quarterly Update Call

    WINTER PARK, Fla., May 14, 2026 (GLOBE NEWSWIRE) --  Streamex Corp. ("Streamex" or the "Company") (NASDAQ:STEX), a technology company focused on the tokenization of commodity real-world assets, today announced that it has filed its Q1 2026 financial results and will host an earnings and corporate update presentation on Wednesday, May 20, 2026, at 4:30 p.m. ET. Henry McPhie, Co-Founder & Chief Executive Officer of Streamex, said: "Q1 2026 was a transformative quarter for Streamex. We raised over $40 million in equity capital, fully deleveraged our balance sheet, and launched GLDY. We made our first yield distribution to GLDY holders, paying investors in gold to hold gold for the first tim

    5/14/26 6:01:22 PM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care